1Pemberton CJ, Johnson ML, Yandle TG, et al. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload[J].Hypertension, 2000,36:355-359
2McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides[J]. Rev Cardiovasc Med, 2003,4 (Suppl 4) :S13 - 19
3Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults [ J ]. Am J Cardiol,2002,90:254 - 258
4Sirithunyanont C, Leowattana W, Sukumalchantra Y, et al. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases[J]. J Med Assoc Thai,2003 ,86 ( Suppl 1 ): S87 - 95
5Cosin AJ, Hernandiz MA, Diez G JL,et al. Value of NTproBNP concentration in an out-of-hospital adult population[ J ]. Rev Esp Cardiol,2003, 56:236 -244
6Nousiainen T, Vanninen E, Jantunen E,et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction[J]. J Intern Med, 2002,251:228 - 234
7Pfister R, Scholz M, Wielckens K, et al. The value of natriuretic peptides NT-pro-BNP and BNP for the assessment of left-ventricular volume and function. A prospective study of 150 patients[J]. Dtsch Med Wochenschr, 2002,127:2605 - 2609
8Rivera M, Cortes R, Mora V, et al. NT-proBNP and atrioventricular plane displacement. relationship and diagnostic implications[J]. Rev Esp Cardiol, 2003, 56:1043 - 1049
9Talwar S, Squire IB, Davies JE, et al. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population[ J]. Eur Heart J, 1999,20:1736 - 1744
10Palladini G, Campana C, Klersy C, et al. Serum N-terminal probrain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis[J]. Circulation, 2003,107:2440 - 2445
3Ogawa Y,Tanmra N,Chusho H,et al.Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart[J].Can J Physiol Pharmacol,2001,79(8):723.
4Pemberton CJ,Johnson ML,Yalldie TG,et al.Deconvolution analysis of cardiac natriuretic peptides during acute volume overload[J].Hypertension,2000,36(2):355.
5Remme WJ,Swedberg K.Task force for the diagnosis and treatment of chronic heart failure,European Society of Cardiology,guidelines for the diagnosis and treatment of chronic heart failure[J].Eur Heart J,2001,22(7):1527.
6Clerico A,Iervasi G,Mariani G.Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans[J].Horm Metab Res,1999,31(9):487.
7Lori BD,Alan SM.Natriuretic peptides[J].J Am Coil Cardiol,2007,50(10):2357.
8Groenning BA,Nilsson JC,sondergaard L,et al.Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohormonal plasma concentrations[J].Eur J Heart Fail,2001,3(6):699.
9Nousiainen T,Vanninen E,Jantunen E,et al.Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction[J].J Intern Med,2002,25l(1):228.
10Dickstein K,Cohen Solal A,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008:the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).Eur Heart J,2008,29 (19):2388-2442.
